Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
Amir GoldkornCatherine TangenMelissa PletsGareth J MorrisonAlexander CunhaTong XuJacek K PinskiSue A InglesTimothy TricheAndrea L HarzstarkManish KohliGary R MacVicarDaniel A VaenaAnthony W CrispinoDavid J McConkeyPrimo N LaraMaha H A HussainDavid I QuinnNicholas J VogelzangIan Murchie ThompsonArchana M AgarwalPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Baseline CTC count in mCSPC is highly prognostic of 7-month PSA and 2-year PFS after adjusting for disease burden and discriminates men who are likely to experience poor survival outcomes.